HCPCS code S0183 – Prochlorperazine maleate oral billing

Key takeaways

S0183 bills oral prochlorperazine maleate, 5 mg, to Medicaid and private payers, not traditional Medicare Part B.

Each unit equals one 5 mg tablet, so a 10 mg dose goes on the claim line as 2 units.

S-codes are not payable by Medicare Part B. For Medicare, use Q0164, which is limited to chemotherapy use.

Most Medicaid programs want the 11-digit NDC on the claim, and many plans set their own daily unit caps.

Common denials, such as the wrong payer, wrong units or a missing NDC, can be caught before submission.

HCPCS code S0183 covers oral prochlorperazine for non-Medicare payers

HCPCS code S0183 is the Level II code for prochlorperazine maleate, oral, 5 mg. One unit equals one 5 mg tablet. S-codes are temporary national codes for Medicaid and private payers, not Medicare. CMS maintains the HCPCS Level II code set, and S0183’s own descriptor points Medicare claims to Q0164.

Prochlorperazine is a phenothiazine antiemetic, once sold under the brand name Compazine. Prescribers use it for nausea and vomiting, including chemotherapy-induced nausea and vomiting (CINV).

At higher doses, it also serves as an adjunct in psychotic disorders. The tablet form is what sets S0183 apart from injectable prochlorperazine, which bills under J0780.

Medicaid and private plans pay S0183, but Medicare Part B never does

Medicaid is where S0183 does most of its work. State programs and commercial insurers recognize S-codes, while traditional Medicare Part B does not pay them. Send S0183 to a Medicare contractor and the claim comes straight back.

Coverage still varies plan by plan inside each payer type. Before your first S0183 claim to a new payer, confirm acceptance through its provider portal or an eligibility check.

S0183 vs Q0164: Medicare’s code only fits a chemotherapy substitute

Q0164 covers the same 5 mg tablet under a much narrower rule. Medicare pays it only when the tablet fully replaces an IV antiemetic at the time of chemotherapy. The regimen also can’t run past 48 hours.

Outside that window, a Medicare patient’s tablets are a Part D pharmacy claim, not a Part B claim from your practice. That leaves four routes for oral prochlorperazine, and the diagram below maps them.

Other oral antiemetics have their own S-codes. Ondansetron tablets, for example, bill under S0119, so match the drug on the order before you pick a code. Confirm current descriptors each year with the AAPC HCPCS code lookup.

Bill one S0183 unit for every 5 mg tablet

The unit math is simple. Divide the prescribed dose by 5 mg, and the result is the unit count. The table covers the doses billers see most.

Many Medicaid and commercial payers also set a daily unit maximum. Each payer defines its own limit, so it differs between plans. Go over it and the line denies, even when the prescription supports the dose. Check the per-day cap in the payer’s drug policy first.

Here is where each detail goes on the claim:

• CMS-1500: Report S0183 on its own line, with the unit count in Box 24G.
• UB-04: Pair S0183 with revenue code 0636, pharmacy drugs requiring detailed coding.
• NDC: Many Medicaid programs require the 11-digit NDC with the N4 qualifier. Check your state’s billing manual before leaving it off.

A clean claim needs the code, units, diagnosis and NDC to match the prescriber’s order before it goes out.

Pair S0183 with the most specific ICD-10 code on the record

Every S0183 claim needs a diagnosis that shows why the patient needs an oral antiemetic. The more specific the code, the easier the claim passes medical necessity review.

R11.2 is the usual pairing for a general antiemetic prescription. For CINV, code the adverse effect and the underlying cancer where the record supports both. Oncology drug policies often expect a documented cancer diagnosis, not a bare symptom code.

S0183 rates come from state Medicaid schedules and payer contracts

CMS publishes no Medicare fee schedule rate for S0183, because Medicare doesn’t pay S-codes. Your reimbursement comes from two other places.

• State Medicaid: Each state sets its own drug rate, often from acquisition cost or Average Wholesale Price (AWP) minus a discount. Look up the current S0183 amount in your state’s drug fee schedule.
• Commercial payers: Your contract sets the rate. If S0183 isn’t listed, ask your payer contract representative. Many plans pay from AWP, so the NDC you report affects the amount.

Prior authorization for S0183 depends on the payer and the state

No universal prior authorization (PA) rule applies to S0183. Medicaid managed care organizations (MCOs) are the most likely to require one, especially for chronic or high-dose use.

Some MCOs want proof that a first-line antiemetic, such as ondansetron, was tried first. State fee-for-service programs vary as well. Some list prochlorperazine as a preferred drug, and others put it on a PA tier.

Commercial payers often apply step therapy to antiemetics. A PA request usually needs the diagnosis, the treatment plan and evidence of medical necessity. Keep the superbill with the PA approval, which makes any later appeal simpler. PA rules change each plan year, so recheck them when a new benefit year starts.

Document these six items before an S0183 claim goes out

Lookup sites stop at the descriptor. An audit goes further and checks the patient record behind the claim. These six items keep that record standing:

• Prescriber order: Drug, dose, oral route, frequency and signature. The units billed must match the order exactly.
• Diagnosis documentation: A provider note giving the clinical reason for prochlorperazine, matching the ICD-10-CM code on the claim.
• Dispensing record: The pharmacy or in-office log with the drug, lot number, quantity and date.
• NDC: The 11-digit National Drug Code from the package you dispensed. Most Medicaid programs and many commercial payers require it.
• Prior authorization record: The PA number on the claim, with the approval letter kept on file.
• Medical necessity statement: For CINV, a note that links the chemotherapy regimen to the antiemetic prescription.

Before you submit, run this five-point check

1. Payer: Medicaid or commercial gets S0183. Medicare gets Q0164 for the chemotherapy substitute, or no Part B claim at all.
2. Units: The dose divided by 5 mg, and within the payer’s daily cap.
3. Diagnosis: The most specific ICD-10-CM code the note supports.
4. NDC: Present, 11 digits, with the N4 qualifier where the payer requires it.
5. PA and place of service: The authorization number is on the claim, and the POS matches where the drug was given or dispensed.

Why S0183 claims get denied, and how to fix each one

S0183 denials follow the same patterns across Medicaid and commercial payers. A structured denial management process stops them from repeating.

• Wrong payer (Medicare with an S-code): S-codes are not payable by Medicare Part B. Resubmit as Q0164 only when the chemotherapy-substitute rule applies. General antiemetic use is not a Part B claim.
• Units over the daily maximum: Recalculate against the payer’s allowed daily dose and correct the claim line.
• Unsupported or missing diagnosis: Get the prescriber’s note on the indication and recode to the most specific ICD-10-CM code.
• No prior authorization: File a retrospective PA with the clinical note attached, or appeal with proof of urgent clinical need.
• Missing or wrong NDC: Verify the NDC from the dispensing record and resubmit with the N4 qualifier.
• Wrong place of service: Pharmacy dispensing for home use takes a different POS than in-office administration. Confirm where the drug was given and fix the code.

Each denial arrives with a claim adjustment reason code (CARC) on the remittance. Match it to the fix above, then check our medical billing denial codes guide for the less common ones.

How Pabau keeps S0183 claims moving after submission

Most S0183 trouble starts at the payer step and only shows up weeks later as a denial. By then, the remittance sits in one place while the order and the note sit in the chart.

Pabau, the practice management platform we build, closes that loop with its claims management software. It supports claim submission, ERA and denial tracking alongside patient records. In the US, claims go out through Claim.MD, with eligibility checks available before the visit.

Remittances post against each claim, so your team can see which S0183 lines paid and which need a corrected resubmission.

Track S0183 claims from submission to payment

Pabau supports claim submission, ERA and denial tracking alongside patient records. Your team sees which drug claims paid and fixes the rest sooner.

Book a demo

Conclusion

Get the payer right first, and S0183 mostly takes care of itself. Medicaid and commercial plans take S0183. Medicare takes Q0164 only for the chemotherapy substitute, and no Part B code otherwise.

After that, the claim depends on details: units against the dose, the NDC and a specific diagnosis. Build the five-point check into every submission, and most of these denials get caught before they leave.

Book a demo to see how Pabau tracks claims and denials for drug codes like S0183.

Continue your research

Need to understand how medical billing denials work at a system level? Denial management in healthcare covers the full denial lifecycle, from reason code identification to appeals workflow.

Looking for a reference on how clean drug claims are structured? What makes a clean claim breaks down the elements that determine first-pass acceptance rates for HCPCS drug codes.

Want to see how electronic remittance data maps back to HCPCS codes? Electronic remittance advice explained covers ERA/835 file structure and how denial CARC codes relate to claim corrections.

Billing another oral antiemetic? HCPCS code S0174 for oral dolasetron walks through the same S-code payer and unit rules for a different drug.

Giving prochlorperazine by injection instead? HCPCS code J0780 for prochlorperazine injection covers dosing units and payer rules for the injectable form.

Frequently asked questions